fda decision: zidesamtinib by nuvalent (2026)

    a full approval or an accelerated approval

    fda decision: zidesamtinib by nuvalent (2026). Best Yes near 100¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 100¢ · Best No: 0¢ · 1 platform

    • Kalshi: Yes 100¢ / No 0¢
    TRADING OPEN

    a full approval or an accelerated approval

    Volume

    $1.5K

    $1.4K 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jan 1, 2027

    ~110 days left

    Category

    Economics

    100¢CHANCE OF YES100%0%
    Yes
    100¢
    Kalshi
    No
    0¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    kalshi
    Kalshi
    Best Yes
    Best No
    Yes
    100¢
    No
    0¢
    Vol
    $1.5K
    $1.4K 24h
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA's decision on Zidesamtinib by Nuvalent in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 100¢: exit costs ~0¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jan 1, 2027
    Time Left110 days
    StatusCLOSED
    CategoryEconomics

    Sign in to join the discussion

    Sign In